Journal article

Long-term Follow-up of Patients with Relapsed or Refractory Non-Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study.

Matthew S Davids, Andrew W Roberts, Vaishalee P Kenkre, William G Wierda, Abhijeet Kumar, Thomas J Kipps, Michelle Boyer, Ahmed Hamed Salem, John C Pesko, Jennifer A Arzt, Margaret Mantas, Su Y Kim, John F Seymour

Clin Cancer Res | Published : 2021


PURPOSE: We previously reported a 44% overall response rate (ORR) with the oral BCL-2 inhibitor venetoclax in a phase I study of relapsed/refractory non-Hodgkin lymphoma (NHL). Complete response (CR) was observed in patients with mantle cell lymphoma [(MCL), 21%, n = 6/28] and follicular lymphoma [(FL), 17%, n = 5/29], and partial response (PR) noted in several patients with Waldenström macroglobulinemia (WM), and marginal zone lymphoma (MZL). Here, we report the long-term outcomes of these four cohorts. PATIENTS AND METHODS: All patients (n = 106) received venetoclax monotherapy in dose cohorts of 200 to 1,200 mg daily until disease progression or unacceptable toxicity. ORR, progression-fre..

View full abstract